Abstract Body

Background

Variants in the STING1/TMEM173 gene influence innate immune signaling. The HAQ haplotype (R71H, G230A, R293Q) and R232H, have been linked to reduced age-related comorbidities in general population and slower HIV progression. This pilot study aimed to investigate how STING1 variants affect immune control, comorbidities, and functional outcomes in People Living with HIV (PLWH).

Methods

Demographic, clinical, and immunological data were collected from 60 PLWH at the ASST Spedali Civili di Brescia outpatient clinic, all providing informed consent. Inclusion criteria: age >50 years, ≥10 years of antiretroviral therapy (ART). Exclusion criteria: psychiatric disorders, use of anticholinergic/psychotropic drugs, high alcohol intake. Patients were genotyped for the STING1 HAQ and R232H variants. Cognition was assessed with the Mini-Mental State Examination and the Clock Drawing Test, motor abilities with the Short Physical Performance Battery. Differences in outcomes between wild-type (WTc) and polymorphisms carriers were assessed using non-parametric tests and ANCOVAs adjusted for HIV duration.

Results

Overall, 32% of PLWH were heterozygous for the HAQ haplotype, 21.7% for the R232H variant. Two individuals were homozygous: one for the HAQ haplotype (HAQ/HAQ) and one for R232H (H/H). Compared with the HAQ group, WTc had longer disease duration, higher CD4 counts, and fewer virological failures, but also a higher prevalence of dyslipidemia (Figure1a). The HAQ/HAQ maintained a controlled viro-immunological profile over 17 years of ART, despite numerous infections, including opportunistic ones. The R232H group had higher CD4 counts, and a trend to hepatopathy, and COVID-19 history (Figure1b). The H/H sustained elite-controller status for 31 years without ART (zenith HIV-RNA 69 copies/ml). No significant cognitive or motor differences were found.

Conclusions

WTc showed better long-term immune control and survival, but a higher prevalence of metabolic comorbidities, likely from prolonged ART. HAQ carriers displayed lower chronic inflammation but poorer infection control, with the HAQ/HAQ showing increased vulnerability to infections. R232H carriers showed stronger immune profiles but higher COVID-19 prevalence, in line with STING1 role in antiviral responses. Notably, the H/H maintained elite-controller status for more than 30 years without ART. Overall, STING1 variants seem to modulate the balance between immune protection, comorbidities, and viral susceptibility in PLWH.

Table or Figure